Biotech Co.* (Country; Symbol)

Pharma Co. (Country)

Change from original agreement

Terms/Details (Date)

Ardais Corp.*

Aventis SA (France)

Expanded deal allowing Aventis to use Ardais technology in evaluating biological targets

Ardais will combine its BIGR Library of tissues and associated patient data with its immunohistochemistry profiling in the effort; terms were not disclosed (4/6)

Dharmacon Inc.*

Bayer Pharmaceuticals Corp.

Expanded agreement for the supply of custom siRNA reagents for use in Bayer target validation and drug discovery

Dharmacon will supply siRNA reagents for about 4,000 gene targets; terms of the deal were not disclosed (3/2)

Gene Logic Inc. (GLGC)

Sankyo Co. Ltd. (Japan)

Multiyear renewal agreement for Sankyo to continue using certain parts of Gene Logic's information services for R&D

Sankyo reduced is access to certain technologies in renewing the deal struck in 2001; terms were not disclosed (4/5)

Gene Logic Inc. (GLGC)

Boehringer Ingelheim International GmbH (Germany)

BI renewed deal to use Gene Logic's information services in R&D programs

BI retains use of the GeneExpress Suite of Data for a multiyear period; terms of the deal were not disclosed (2/20)

Genmab A/S (Denmark; CSE:GEN)

F. Hoffmann-La Roche Ltd. (Switzerland)

Roche selected two antibodies as candidates for clinical development under their collaboration

Specific details related to the actions were not disclosed; Genmab can earn milestone and royalty payments in the alliance (3/19)

Isotechnika Inc. (Canada; TSE:ISA)

Hoffmann-La Roche Inc.

Isotechnika will take over development of transISA247 in renal transplantation

Roche still can get all rights in transplant indications through Phase II trials by paying an option fee, milestones and 70% of development costs; Isotechnika would get royalties and retains rights outside transplantation (4/20)

LION Bioscience AG (Germany; LEON)

GlaxoSmithKline plc (UK)

GSK renewed its license to LION's SRS data-integration platform

Terms of the deal were not disclosed (4/7)

MorphoSys AG (Germany; FSE:MOR)

Centocor Inc. (unit of Johnson & Johnson)

MorphoSys will generate antibodies against a target selected by Centocor under their December 2000 collaboration

MorphoSys stands to receive undisclosed license fees, milestone payments and sales royalties; MorphoSys already generated two antibodies under the deal (3/8)

Serologicals Corp. (SERO)

Novo Nordisk A/S (Denmark)

Expanded deal for worldwide distribution of human recombinant insulin for use in cell culture media markets

The deal on distributing Serologicals' products was extended through 2006; terms were not disclosed (3/9)

Transkaryotic Therapies Inc. (TKTX)

Aventis Pharmaceuticals Inc.

Aventis returned to TKT all rights to Dynepo in Europe and everywhere outside the U.S.

TKT will pay Aventis a scaled royalty on Dynepo sales; Aventis obtained an option on certain TKT gene-therapy technology for one year; TKT is responsible for any legal expenses in Europe over the product and half of any such expenses in the U.S. (3/26)

Tranzyme Inc.*

Becton, Dickinson & Co.

Expanded deal under which BD will continue to get access to Tranzyme's gene delivery and expression technologies

Companies also will explore use of technologies to specific cell types of interest to BD, in exchange for R&D funding for Tranzyme; BD would pay royalties on sales of any resulting products (3/2)

Tularik Inc. (TLRK)

Sankyo Co. Ltd. (Japan)

Sankyo expanded the collaboration by selecting up to four GPCR targets for further research for one year

Tularik is entitled to further financial support, as well as potenial milestones and royalties on any resulting products; the companies are sharing costs and profits from the deal (3/8)

Vivus Inc. (VVUS)

Tanabe Seikayu Co. Ltd. (Japan)

Vivus gained an $8.5M line of credit from Tanabe for development of avanafil (TA-1790)

Vivus licensed the erectile dysfunction product from Tanabe in 2001; the product is in Phase II trials (4/6)


Guilford Pharmaceuticals Inc. (GLFD)

Pfizer Inc.

Guilford regained all rights to NAALADase inhibitors that were covered under their May 2003 collaboration

Pfizer ended the deal one day before it would have owed a $10M milestone payment; Guilford, which received $5M in the deal, will seek a new partner (3/30)

Maxim Pharmaceuticals Inc. (MAXM)

Shire Pharmaceuticals Group plc (UK)

Maxim regained rights to the MX2105 series of vascular targeting agents for cancer

BioChem Pharma licensed the series in 2000; Shire, which acquired BioChem, was getting out of oncology; Shire would earn milestone and royalty payments if any drugs from the series are developed (3/17)

PPL Therapeutics plc (UK; LSE:PPH)

Bayer Biological Products

Companies terminated their agreement for development of recombinant alpha-1 antitrypsin

The move followed a June 2003 decision to put the program on hold; Bayer gets a royalty-free right to develop the product later for congenital deficiency, cystic fibrosis or chronic obstructive pulmonary disease, and PPL retains rights elsewhere (2/16)

Regeneron Pharmaceuticals Inc. (REGN)

Novartis Pharma AG (Switzerland)

Novartis decided to forgo its rights under the collaboration to develop the Interleukin-1 Trap product, after Regeneron would not revise terms following a Phase II trial that missed its primary endpoint

Novartis has paid about $102M to date in up- front and milestone payments, and development expenses; Regeneron plans to move the product into a Phase IIb trial in rheumatoid arthritis in 2H:04; each firm retains rights to collaborate on other IL-1 antagonists being developed independently that are in earlier-stage development (2/27); Novartis agreed to pay $42.75M to satisfy its remaining obligation to fund development costs (4/1)

Sepracor Inc. (SEPR)

Ross Products Division of Abbott Laboratories

The co-promotion deal for Xopenex will be terminated effective Dec. 31, 2004; the product is a bronchodilator

Sepracor is ending the deal as it increases its sales force; it will pay Ross $30M by the end of 2005 and $3M by the end of 2006 (3/25)

SynX Pharma Inc. (Canada; TSE:SYY)

Ortho-Clinical Diagnostics Inc. (unit of Johnson & Johnson)

Synx reacquired rights to technology for diagnosing Alzheimer's licensed to Ortho in October 2002

Ortho terminated the deal and returned all rights to SynX, which said it intends to continue development (3/5)

Targeted Genetics Corp. (TGEN)

Elan Corp. plc (Ireland)

Companies formally ended their Emerald Gene Systems Ltd. joint venture

Work in the venture had ended in 2002; Elan converted its Series B preferred stock into 4.3M TGEN shares (4/6)


# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; TSE = Toronto Stock Exchange.